<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36059554</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques.</ArticleTitle><Pagination><StartPage>949248</StartPage><MedlinePgn>949248</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">949248</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.949248</ELocationID><Abstract><AbstractText>To cope with the decline in COVID-19 vaccine-induced immunity caused by emerging SARS-CoV-2 variants, a heterologous immunization regimen using chimpanzee adenovirus vectored vaccine expressing SARS-CoV-2 spike (ChAd-S) and an inactivated vaccine (IV) was tested in mice and non-human primates (NHPs). Heterologous regimen successfully enhanced or at least maintained antibody and T cell responses and effectively protected against SARS-CoV-2 variants in mice and NHPs. An additional heterologous booster in mice further improved and prolonged the spike-specific antibody response and conferred effective neutralizing activity against the Omicron variant. Interestingly, priming with ChAd-S and boosting with IV reduced the lung injury risk caused by T cell over activation in NHPs compared to homologous ChAd-S regimen, meanwhile maintained the flexibility of antibody regulation system to react to virus invasion by upregulating or preserving antibody levels. This study demonstrated the satisfactory compatibility of ChAd-S and IV in prime-boost vaccination in animal models.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 He, Mao, Zhang, Gao, Bai, Cui, Liu, An, Wang, Yan, Yang, Song, Song, Liu, Yuan, Sun, Zhao, Bian, Wu, Huang, Li, Wang, Liang and Xu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jialu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Bopei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Chaoqiang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Xujia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jinghuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lifang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Ziyang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yadi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Guangzhou Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jincun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Guangzhou Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Weijin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Changgui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junzhi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000261" MajorTopicYN="Y">Adenoviruses, Simian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008251" MajorTopicYN="N">Macaca</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword><Keyword MajorTopicYN="N">animal model</Keyword><Keyword MajorTopicYN="N">heterologous immunization</Keyword><Keyword MajorTopicYN="N">protective effectiveness</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>5</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36059554</ArticleId><ArticleId IdType="pmc">PMC9428284</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.949248</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
WHO . COVID-19 vaccine tracker and landscape. Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.</Citation></Reference><Reference><Citation>
WHO . Criteria for COVID-19 vaccine prioritization. Available at: https://www.who.int/publications/m/item/criteria-for-covid-19-vaccine-prioritization.</Citation></Reference><Reference><Citation>
WHO . WHO coronavirus (COVID-19) dashboard. Available at: https://covid19.who.int/.</Citation></Reference><Reference><Citation>Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. . Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med (2021) 384:80&#x2013;2. doi: 10.1056/NEJMc2032195</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2032195</ArticleId><ArticleId IdType="pmc">PMC7727324</ArticleId><ArticleId IdType="pubmed">33270381</ArticleId></ArticleIdList></Reference><Reference><Citation>Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, Van Eeckhoudt S, et al. . Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect (2021) 10:1495&#x2013;8. doi: 10.1080/22221751.2021.1953403</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1953403</ArticleId><ArticleId IdType="pmc">PMC8300930</ArticleId><ArticleId IdType="pubmed">34232116</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, et al. . COVID-19 vaccine - long term immune decline and breakthrough infections. Vaccine (2021) 39:6984&#x2013;9. doi: 10.1016/j.vaccine.2021.10.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.10.038</ArticleId><ArticleId IdType="pmc">PMC8556595</ArticleId><ArticleId IdType="pubmed">34763949</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegu A, O'Connell SE, Schmidt SD, O'Dell S, Talana CA, Lai L, et al. . Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Sci (New York NY) (2021) 373:1372&#x2013;7. doi: 10.1126/science.abj4176</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj4176</ArticleId><ArticleId IdType="pmc">PMC8691522</ArticleId><ArticleId IdType="pubmed">34385356</ArticleId></ArticleIdList></Reference><Reference><Citation>Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, et al. . Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe (2021) 29:516&#x2013;21.e3. doi: 10.1016/j.chom.2021.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.03.009</ArticleId><ArticleId IdType="pmc">PMC7980225</ArticleId><ArticleId IdType="pubmed">33798491</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. . Omicron extensively but incompletely escapes pfizer BNT162b2 neutralization. Nature (2022) 602:654&#x2013;6. doi: 10.1038/s41586-021-04387-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04387-1</ArticleId><ArticleId IdType="pmc">PMC8866126</ArticleId><ArticleId IdType="pubmed">35016196</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Wang R, Gilby NB, Wei GW. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. ArXiv (2021) 62(2):412&#x2013;422. doi: 10.1021/acs.jcim.1c01451</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.1c01451</ArticleId><ArticleId IdType="pmc">PMC8751645</ArticleId><ArticleId IdType="pubmed">34989238</ArticleId></ArticleIdList></Reference><Reference><Citation>Excler JL, Kim JH. Novel prime-boost vaccine strategies against HIV-1. Expert Rev Vaccines (2019) 18:765&#x2013;79. doi: 10.1080/14760584.2019.1640117</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2019.1640117</ArticleId><ArticleId IdType="pubmed">31271322</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol (2009) 21:346&#x2013;51. doi: 10.1016/j.coi.2009.05.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2009.05.016</ArticleId><ArticleId IdType="pmc">PMC3743086</ArticleId><ArticleId IdType="pubmed">19500964</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Parker C, Taaffe J, Sol&#xf3;rzano A, Garc&#xed;a-Sastre A, Lu S. Heterologous HA DNA vaccine prime&#x2013;inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine (2008) 26:3626&#x2013;33. doi: 10.1016/j.vaccine.2008.04.073</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.04.073</ArticleId><ArticleId IdType="pmc">PMC2802517</ArticleId><ArticleId IdType="pubmed">18538900</ArticleId></ArticleIdList></Reference><Reference><Citation>van Diepen MT, Chapman R, Douglass N, Galant S, Moore PL, Margolin E, et al. . Prime-boost immunizations with DNA, modified vaccinia virus Ankara, and protein-based vaccines elicit robust HIV-1 tier 2 neutralizing antibodies against the CAP256 superinfecting virus. J Virol (2019) 93:e02155&#x2013;18. doi: 10.1128/JVI.02155-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02155-18</ArticleId><ArticleId IdType="pmc">PMC6450106</ArticleId><ArticleId IdType="pubmed">30760570</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. . Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet (2020) 396:887&#x2013;97. doi: 10.1016/S0140-6736(20)31866-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31866-3</ArticleId><ArticleId IdType="pmc">PMC7471804</ArticleId><ArticleId IdType="pubmed">32896291</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. . BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. Nature (2021) 595(7868):572&#x2013;577. doi: 10.1038/s41586-021-03653-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03653-6</ArticleId><ArticleId IdType="pubmed">34044428</ArticleId></ArticleIdList></Reference><Reference><Citation>Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J Clin Invest (2021) 131 :e149335. doi: 10.1172/JCI149335</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149335</ArticleId><ArticleId IdType="pmc">PMC8121504</ArticleId><ArticleId IdType="pubmed">33822770</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine (2010) 28:2999&#x2013;3007. doi: 10.1016/j.vaccine.2010.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.02.006</ArticleId><ArticleId IdType="pmc">PMC2847033</ArticleId><ArticleId IdType="pubmed">20170767</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Zhang L, Zhang C, Hong K, Shao Y, Huang Z, et al. . DNA Prime-protein boost using subtype consensus env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China. Hum Vaccines Immunother (2012) 8:1630&#x2013;7. doi: 10.4161/hv.21648</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.21648</ArticleId><ArticleId IdType="pmc">PMC3601137</ArticleId><ArticleId IdType="pubmed">23111170</ArticleId></ArticleIdList></Reference><Reference><Citation>Malherbe DC, Vang L, Mendy J, Barnette PT, Spencer DA, Reed J, et al. . Modified adenovirus prime-protein boost clade c HIV vaccine strategy results in reduced viral DNA in blood and tissues following tier 2 SHIV challenge. Front Immunol (2020) 11:626464. doi: 10.3389/fimmu.2020.626464</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.626464</ArticleId><ArticleId IdType="pmc">PMC7917243</ArticleId><ArticleId IdType="pubmed">33658998</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Mao Q, An C, Zhang J, Gao F, Bian L, et al. . Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect (2021) 10:629&#x2013;37. doi: 10.1080/22221751.2021.1902245</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1902245</ArticleId><ArticleId IdType="pmc">PMC8009122</ArticleId><ArticleId IdType="pubmed">33691606</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, He Q, An C, Mao Q, Gao F, Bian L, et al. . Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerg Microbes Infect (2021) 10:1598&#x2013;608. doi: 10.1080/22221751.2021.1957401</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1957401</ArticleId><ArticleId IdType="pmc">PMC8381941</ArticleId><ArticleId IdType="pubmed">34278956</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, et al. . Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med (2022) 28:401&#x2013;9. doi: 10.1038/s41591-021-01677-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01677-z</ArticleId><ArticleId IdType="pmc">PMC8863573</ArticleId><ArticleId IdType="pubmed">35087233</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Status of COVID-19 vaccines within WHO EUL/PQ evaluation process updated.</Citation></Reference><Reference><Citation>Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. . Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med (2021) 27:1530&#x2013;5. doi: 10.1038/s41591-021-01464-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01464-w</ArticleId><ArticleId IdType="pmc">PMC8440177</ArticleId><ArticleId IdType="pubmed">34312554</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu NC, Chi H, Tu YK, Huang YN, Tai YL, Weng SL, et al. . To mix or not to mix? a rapid systematic review of heterologous prime-boost covid-19 vaccination. Expert Rev Vaccines (2021) 20:1211&#x2013;20. doi: 10.1080/14760584.2021.1971522</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1971522</ArticleId><ArticleId IdType="pmc">PMC8425437</ArticleId><ArticleId IdType="pubmed">34415818</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, et al. . Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med (2021) 27:1525&#x2013;9. doi: 10.1038/s41591-021-01449-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01449-9</ArticleId><ArticleId IdType="pmc">PMC8440184</ArticleId><ArticleId IdType="pubmed">34262158</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. . Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect (2020) 9:680&#x2013;6. doi: 10.1080/22221751.2020.1743767</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1743767</ArticleId><ArticleId IdType="pmc">PMC7144318</ArticleId><ArticleId IdType="pubmed">32207377</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Nie S, Wang Y, Long Q, Zhu H, Zhang X, et al. . Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study. Signal Transduct Target Ther (2021) 6:197. doi: 10.1038/s41392-021-00611-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00611-6</ArticleId><ArticleId IdType="pmc">PMC8129700</ArticleId><ArticleId IdType="pubmed">34006847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S, Zhao Y, Yu W, Yang Y, Gao J, Wang J, et al. . Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct Target Ther (2020) 5:157. doi: 10.1038/s41392-020-00269-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00269-6</ArticleId><ArticleId IdType="pmc">PMC7434851</ArticleId><ArticleId IdType="pubmed">32814760</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. . Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight (2019) 4 :e123158. doi: 10.1172/jci.insight.123158</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.123158</ArticleId><ArticleId IdType="pmc">PMC6478436</ArticleId><ArticleId IdType="pubmed">30830861</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med (2021) 27:1205&#x2013;11. doi: 10.1038/s41591-021-01377-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. . Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature (2021) 590:630&#x2013;4. doi: 10.1038/s41586-020-03041-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03041-6</ArticleId><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Mao Q, Peng X, He Z, Lu S, Zhang J, et al. . Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. Signal Transduct Target Ther (2022) 7:69. doi: 10.1038/s41392-022-00926-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00926-y</ArticleId><ArticleId IdType="pmc">PMC8892123</ArticleId><ArticleId IdType="pubmed">35241645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. . T Cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med (2021) 27:270&#x2013;8. doi: 10.1038/s41591-020-01194-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01194-5</ArticleId><ArticleId IdType="pubmed">33335323</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi H, Chen X, Chu C, Liu D, Ma W, Wang Y, et al. . Tfh cell differentiation and their function in promoting b-cell responses. Adv Exp Med Biol (2014) 841:153&#x2013;80. doi: 10.1007/978-94-017-9487-9_6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-94-017-9487-9_6</ArticleId><ArticleId IdType="pubmed">25261207</ArticleId></ArticleIdList></Reference><Reference><Citation>Piadel K, Haybatollahi A, Dalgleish AG, Smith PL. Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2. J Gen Virol (2022) 103 :001698. doi: 10.1099/jgv.0.001698</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001698</ArticleId><ArticleId IdType="pmc">PMC8895615</ArticleId><ArticleId IdType="pubmed">35014605</ArticleId></ArticleIdList></Reference><Reference><Citation>Eickhoff CS, Terry FE, Peng L, Meza KA, Sakala IG, Van Aartsen D, et al. . Highly conserved influenza T cell epitopes induce broadly protective immunity. Vaccine (2019) 37:5371&#x2013;81. doi: 10.1016/j.vaccine.2019.07.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.07.033</ArticleId><ArticleId IdType="pmc">PMC6690779</ArticleId><ArticleId IdType="pubmed">31331771</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . WHO/BS.2020.2403 establishment of the WHO international standard and reference panel for anti-SARS-CoV-2 antibody (Accessed November 18).</Citation></Reference><Reference><Citation>Zhang M, Zhang S. T Cells in fibrosis and fibrotic diseases. Frontiers in Immunology (2020) 11:1142. doi: 10.3389/fimmu.2020.01142</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01142</ArticleId><ArticleId IdType="pmc">PMC7333347</ArticleId><ArticleId IdType="pubmed">32676074</ArticleId></ArticleIdList></Reference><Reference><Citation>Agita A, Alsagaff MT. Inflammation, immunity, and hypertension. Acta Med Indonesiana (2017) 49:158&#x2013;65. doi: 10.1161/HYPERTENSIONAHA.110.163576</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.110.163576</ArticleId><ArticleId IdType="pubmed">28790231</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L, Gao F, Zhang J, He Q, Mao Q, Xu M, et al. . Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev Vaccines (2021) 20:365&#x2013;73. doi: 10.1080/14760584.2021.1903879</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1903879</ArticleId><ArticleId IdType="pmc">PMC8054487</ArticleId><ArticleId IdType="pubmed">33851875</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L, Gao Q, Gao F, Wang Q, He Q, Wu X, et al. . Impact of the delta variant on vaccine efficacy and response strategies. Expert Rev Vaccines (2021) 20:1201&#x2013;9. doi: 10.1080/14760584.2021.1976153</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1976153</ArticleId><ArticleId IdType="pmc">PMC8442750</ArticleId><ArticleId IdType="pubmed">34488546</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WB, Liang Y, Jin YQ, Zhang J, Su JG, Li QM. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. J Mol Graphics Model (2021) 109:108035. doi: 10.1016/j.jmgm.2021.108035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmgm.2021.108035</ArticleId><ArticleId IdType="pmc">PMC8447841</ArticleId><ArticleId IdType="pubmed">34562851</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, et al. . Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet (2022) 399:521&#x2013;9. doi: 10.1016/S0140-6736(22)00094-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00094-0</ArticleId><ArticleId IdType="pmc">PMC8782575</ArticleId><ArticleId IdType="pubmed">35074136</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>